|Articles|May 12, 2022
Live Broadcast to Explore a Second Line Treatment Option for HER2+ Metastatic Breast Cancer
Advertisement
In an upcoming broadcast, Joyce O'Shaughnessy, MD, Shanu Modi, MD, and Anne O’Dea, MD will discuss the approach and goals of the management of certain patients with HER2+ metastatic breast cancer (mBC) and take a deeper look at the burden and unmet needs of the disease. Additionally, they will discuss a second line treatment option for HER2+ mBC.
To obtain expert perspective and learn about the efficacy and safety data of this treatment option, watch the live broadcast on 6/16/2022. To register for the event, visit
PP-US-ENB-1270 05/22
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
3
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
4
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma
5


































